NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.

Author: Tezilkree Vilmaran
Country: Pakistan
Language: English (Spanish)
Genre: Education
Published (Last): 22 April 2017
Pages: 52
PDF File Size: 15.74 Mb
ePub File Size: 15.99 Mb
ISBN: 556-4-49686-473-8
Downloads: 60462
Price: Free* [*Free Regsitration Required]
Uploader: Fenribei

For consumers, the great value in generics is getting it cheaper. Piramal’s Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience.

On Friday, Piramal Healthcare stocks went up to Rs All news from India. It will, however, continue research in drug discovery through an affiliate company. Combined with existing product offerings, Abbott is uniquely positioned to meet the needs of one of the world’s fastest-growing pharmaceutical markets,” he said. These other players are not even interested in doing that. Abbott has been operating in India for of its years, and has popular pharmaceutical brands including the antacid Digene and painkiller Brufen.

Please login to the form below. The potential to expand with very high priced specialty products is seriously limited. BOthe U. Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities. Abbott has completed its acquisition of Piramal’s Healthcare Solutions business. Healthcxre have to create a whole organization, and that takes time. Reliance to buy majority stake in renewable energy services firm Kanoda.


The hunter has become the hunted. Industry forecaster IMS Health predicts leading emerging markets will show healtthcare pharmaceuticals sales growth of 14 to 17 percent throughagainst just 3 to 6 percent a year for developed markets. For the year ended March 31,Piramal Healthcare posted a consolidated total operating income of Rs 3, crore, up by BOas global drugmakers look to boost their presence in emerging markets.

More news by Piramal Healthcare. Jude Medical set to close.

Abbott To Acquire Piramal Healthcare Unit For $B | VCCircle

Over the past ten years, Abbott has established a leading presence in emerging markets and now more than 20 per cent of the company’s total sales are generated in these growing economies. The Abbott-Piramal deal is the latest in a wave of consolidation within the global pharmaceutical industry over the past few years. BOis booming as governments battle rising healthcare costs. The Abbott deal is the fourth biggest acquisition of an Indian drug business by a foreign drug maker in the last three years.

Abbott to pay $ billion for unit of India’s Piramal | Reuters

Abbott will pay Rs per share. According to Reuters, Abbott was advised by Morgan Stanley. It allows Abbott to commercialize two dozen Zydus Cadila drugs in 15 emerging markets.


To use all functions of this page, please activate cookies in your browser. Obviously, whoever wants to strengthen Indian presence through buyouts, will sllutions to shell out much more due to the higher demand for Indian assets. PMHub Add my company Any category Abbott announced it intends to close the acquisition of St.

Wharton professor of healthcare management Patricia Danzon agrees. All Comments Your Activity.

Abbott buys Piramal’s Healthcare Solutions

It is not so much a concern about the downside, but about how we maximize the opportunity. Disagreements over valuation have prevented more deals from getting done.

Facts, background information, dossiers. Globalization is not just for manufacturers. It is paying roughly 8. This is the 2nd-largest deal ever in the Indian pharma industry, just behind Daiichi Sankyo’s takeover of Ranbaxy in India’s rapid pharmaceutical market growth is being driven largely by branded generics. Leave Your Comment s.